Sangamo BioSciences (SGMO) PT Raised to $30 at Barclays
Barclays raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $30.00 (from $20.00) while maintaining a Overweight rating.
Analyst Gena Wang ups the price target to reflect technology capabilities at the company and progress in clinical programs. The analyst says the with KITE/GILD to exclusive license use of SGMO's ZFN platform in allogeneic and autologous cell therapies is another boost to the ZFN platform and will now eye data on HemoA.